19/04/2026
Taurine is one of the most studied amino acids in metabolic research and one of the least discussed outside it. The 2024 Tzang meta-analysis in Nutrition & Diabetes pooled data from randomized controlled trials of taurine supplementation and measured every major marker in the metabolic syndrome cluster. The results are more consistent and more clinically meaningful than most people realize.
Taurine is a sulfur-containing amino acid. The body synthesizes it from cysteine, but endogenous production does not always meet demand, which is why it is classified as conditionally or semi-essential. It is concentrated in the heart, brain, retina, and skeletal muscle. Plasma and tissue taurine levels are consistently lower in people with type 2 diabetes, obesity, and cardiovascular disease than in healthy controls, a pattern documented across multiple populations.
The 2024 meta-analysis pulled from randomized trials using doses between 0.5 and 6 grams per day. Against placebo, taurine supplementation significantly reduced systolic blood pressure by 4 mmHg. Diastolic blood pressure fell by 1.5 mmHg. Triglycerides dropped by 18.3 mg/dL. Total cholesterol fell by 8.3 mg/dL and LDL cholesterol by 6.5 mg/dL. Fasting glucose decreased by 5.9 mg/dL. The HOMA-IR index, a measure of insulin resistance, fell by 0.69 units. Fasting insulin decreased by 1.5 mU/L. HbA1c trended down by 0.34 percent, a borderline signal. Every endpoint moved in the direction that favors metabolic health. No effect on body weight or BMI, which actually strengthens the mechanistic case because the benefits are not mediated by weight loss.
For context on magnitude, a 4 mmHg systolic reduction is roughly what you would expect from first-line antihypertensive monotherapy at standard doses. An 18 mg/dL triglyceride drop is comparable to what EPA/DHA at 2 to 4 grams per day produces. A 0.69 HOMA-IR reduction is a substantial insulin sensitivity improvement. These are not marginal biomarker shifts. They are clinically relevant changes hit by a single amino acid with no observed safety signal.
The mechanisms that map to these outcomes are well characterized in the literature. Taurine enhances endothelial nitric oxide availability and modulates vascular tone, which plausibly explains the blood pressure reduction. It conjugates with bile acids in the liver and promotes f***l bile acid excretion, increasing hepatic demand for cholesterol as substrate and reducing circulating cholesterol and triglyceride loads. It appears to support pancreatic beta-cell function and improve insulin signaling at peripheral tissues, which maps onto the observed improvements in fasting glucose, fasting insulin, and HOMA-IR.
The caveats worth knowing. Trial sizes have generally been modest, typically 20 to 100 participants per arm. Durations have ranged from days to a year, and most are in the weeks-to-months range, so we do not have long-duration hard cardiovascular endpoint data from randomized trials. Populations skew toward metabolic syndrome, type 2 diabetes, obesity, and hepatic dysfunction rather than the healthy general population. Effects in healthy individuals without metabolic impairment may be smaller or harder to detect. A 2025 meta-analysis in overweight and obese adults identified 3 grams per day as the threshold below which glycemic improvements become inconsistent, suggesting dose matters.
Practically, most trials showing meaningful effects used 3 grams per day, usually in divided doses with meals. Taurine is classified as generally recognized as safe by the FDA. Adverse events in the meta-analysis were statistically indistinguishable from placebo and limited to mild gastrointestinal complaints, headaches, and transient fatigue. As with any intervention in people on antihypertensive medication, diabetes medication, or with liver or kidney disease, talk to a clinician before adding it.
The broader point. Taurine has meta-analysis-level evidence for improving blood pressure, lipids, glycemic control, and insulin sensitivity simultaneously, with no weight or safety trade-offs. It is remarkable how little that data shapes the way this amino acid is discussed.
Tzang CC, et al. Nutr Diabetes. 2024;14(1):29. Guan L, Miao P. Eur J Pharmacol. 2020;885:173533. Ran L, et al. Nutrients. 2025;17(1):4.